From China, bridging biopharmaceutical innovation in Korea
Recently, the 2026 Hubei–Korea Future Cooperation Exchange Event was successfully held in Wuhan, China. As an important platform for efficient collaboration between Chinese and Korean industries and capital, the event brought together government agencies, financial institutions, well-known enterprises, and industry representatives from both countries to conduct in-depth exchanges on strategic emerging industries, with a focus on biomedicine.
During a panel discussion, Ms. Zhao Dandan, Director of Operation at Chime Biologics, shared insights and practical experiences on the synergistic development of the biopharmaceutical industries in China and Korea, highlighting Chime Biologics' unique value in the global biopharma supply chain.
Korea's Biopharma Industry: From Rise to Upgrading
Over the past decade, Korea has achieved rapid development in the field of large-molecule biologics.
By initially leveraging the transfer of pharmaceutical manufacturing from Europe and the United States, Korea has transformed biologics CMC development and commercial production into a key high-tech national industry, giving rise to several large-scale CDMOs with global competitiveness.
However, beneath this successful trajectory, structural challenges have gradually emerged:
The scale-driven CMO/CDMO model primarily serves large global pharmaceutical companies. The high-investment, high-return business model concentrates resources on late-stage and commercial development. The early-stage development needs of local innovative biopharma companies remain underserved. The Rise of Chinese Capabilities: Reshaping Industrial Supply Side Capacity. With the rapid development of China's biopharmaceutical industry, the industry landscape is undergoing profound changes.
In the CDMO and upstream supply chain sectors, China has already produced a number of globally competitive enterprises. Following several years of rapid growth and consolidation, leading players have begun to take shape, presenting new industrial capability characteristics:
End-to-end capabilities covering everything from early development to commercial production. Execution systems that combine efficiency and cost advantages. Development pathways that support both innovative drugs and biosimilars. This capability set precisely fills critical gaps in the Korean biopharma industry at different stages of its development. Chime Biologics: A Key Bridge Connecting Innovation in China and Korea. Within this industrial evolution, Chime Biologics is gradually becoming an important partner for Korean biopharma companies.
Leveraging its international technology systems and efficient execution capabilities, Chime Biologics offers multi-tiered value to its Korean clients:
Empowering Early-Stage Innovation Development: Supporting Korean local innovative biopharma companies in achieving more efficient and cost-effective CMC development in the early R&D phase, accelerating project progressSupporting Scalable Competition for Biosimilars: Providing efficient and competitively priced commercial production solutions for new players entering the biosimilar marketBuilding Long-Term Strategic Partnerships: Empowering Korean innovative biologics and biosimilars to reach global markets – particularly emerging markets such as ASEAN, the Middle East, and North Africa, which become accessible as affordability barriers are lowered, driven by the highly efficient supply chain of China's biologics manufacturingLooking ahead, Chime Biologics will continue to deepen collaboration with partners in Korea and around the world, helping to bring more innovative therapies to market faster and benefit patients globally.
